Clinical Trial

Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients

Study acronym: BK-AE-nC1INH
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated July 2, 2025 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
To assess the efficacy of prophylactic treatment with deucrictibant extended release (XR) tablet versus placebo in preventing angioedema attacks, and to also assess the efficacy of deucrictibant soft capsules as on-demand treatment versus placebo in achieving angioedema symptom relief during acute attacks.
Trial Details
NCT Number NCT07046806
Lead Sponsor Institute for Asthma and Allergy
Conditions Hereditary Angioedema (HAE), Angioedema, Bradykinin-mediated Angioedema, C1 Inhibitor Deficiency
Enrollment 10 participants
Start Date 2025-03-10
Primary Completion 2026-04-01 (estimated)
Study Completion 2026-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-02